Mapping of brain function after MPTP-induced neurotoxicity in a primate Parkinson's disease model

Neuroimage. 2003 Oct;20(2):1064-75. doi: 10.1016/S1053-8119(03)00348-3.

Abstract

Neurophysiological studies of the brain in normal and Parkinson's disease (PD) patients have indicated intricate connections for basal ganglia-induced control of signaling into the motor cortex. To investigate if similar mechanisms are controlling function in the primate brain (Macaca fascicularis) after MPTP-induced neurotoxicity, we conducted PET studies of cerebral blood flow, oxygen and glucose metabolism, dopamine transporter, and D2 receptor function. Our observations after MPTP-induced dopamine terminal degeneration of the caudate and putamen revealed increased blood flow (15%) in the globus pallidus (GP), while blood flow was moderately decreased (15-25%) in the caudate, putamen, and thalamus and 40 % in the primary motor cortex (PMC). Oxygen extraction fraction was moderately increased (10-20%) in other brain areas but the thalamus, where no change was observable. Oxygen metabolism was increased in the GP and SMA (supplementary motor area including premotor cortex, Fig. 3) by a range of 20-40% and decreased in the putamen and caudate and in the PMC. Glucose metabolism was decreased in the caudate, putamen, thalamus, and PMC (range 35-50%) and enhanced in the GP by 15%. No change was observed in the SMA. In the parkinsonian primate, [(11)C]CFT (2beta-carbomethoxy-3beta-(4-fluorophenyltropane) dopamine transporter binding was significantly decreased in the putamen and caudate (range 60-65%). [(11)C]Raclopride binding of dopamine D(2) receptors did not show any significant changes. These experimental results obtained in primate studies of striato-thalamo-cortico circuitry show a similar trend as hypothetized in Parkinson's disease-type degeneration.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine*
  • Animals
  • Brain / diagnostic imaging
  • Brain / pathology
  • Brain / physiopathology*
  • Brain Chemistry / physiology
  • Brain Mapping*
  • Cerebrovascular Circulation / physiology
  • Dopamine Agents / toxicity*
  • Dopamine Plasma Membrane Transport Proteins
  • Energy Metabolism / physiology
  • Glucose / metabolism
  • Macaca fascicularis
  • Magnetic Resonance Imaging
  • Male
  • Membrane Glycoproteins*
  • Membrane Transport Proteins / metabolism
  • Motor Activity / physiology
  • Nerve Tissue Proteins*
  • Oxygen / blood
  • Oxygen Consumption / physiology
  • Parkinson Disease, Secondary / chemically induced
  • Parkinson Disease, Secondary / pathology
  • Parkinson Disease, Secondary / physiopathology*
  • Receptors, Dopamine D2 / drug effects
  • Receptors, Dopamine D2 / metabolism
  • Reproducibility of Results
  • Tomography, Emission-Computed

Substances

  • Dopamine Agents
  • Dopamine Plasma Membrane Transport Proteins
  • Membrane Glycoproteins
  • Membrane Transport Proteins
  • Nerve Tissue Proteins
  • Receptors, Dopamine D2
  • 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
  • Glucose
  • Oxygen